In Friday’s Wall Street session, Castle Biosciences Inc (NASDAQ:CSTL) shares traded at $27.32, down -1.05% from the previous session.
CSTL stock price is now -2.80% away from the 50-day moving average and 1.47% away from the 200-day moving average. The market capitalization of the company currently stands at $765.23M.
With the price target of $25, Guggenheim recently initiated with Buy rating for Castle Biosciences Inc (NASDAQ: CSTL). On January 05, 2023, Scotiabank recently initiated its ‘Sector Outperform’ rating on the stock quoting a target price of $54, while ‘Stephens’ rates the stock as ‘Overweight’
In other news, BRADBURY DANIEL, Director sold 7,867 shares of the company’s stock on Feb 05 ’25. The stock was sold for $221,637 at an average price of $28.17. Upon completion of the transaction, the Director now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 05 ’25, Officer Daniel Bradbury bought 7,867 shares of the business’s stock. A total of $221,220 was incurred on buying the stock at an average price of $28.12. A total of 3.09% of the company’s stock is owned by insiders.
During the past 12 months, Castle Biosciences Inc has had a low of $16.97 and a high of $35.84. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 7.78, and a quick ratio of 7.64. According to the stock market information, the enterprise value for the company is $512114464, which is based on a 136.67 price-to-earnings ratio, a 10.09 price-to-earnings-growth ratio, and a beta of 0.94. The fifty day moving average price for CSTL is $28.1076 and a two-hundred day moving average price translates $26.923426 for the stock.
The latest earnings results from Castle Biosciences Inc (NASDAQ: CSTL) was released for 2024-09-30. The net profit margin was 1.95% and return on equity was 1.47% for CSTL. The company reported revenue of $85.78 million for the quarter, compared to $61.49 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 39.5 percent.
